Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for osteoporosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. BACKGROUND: Corticosteroid treatment is considered the 'gold standard' for Duchenne muscular dystrophy (DMD); however, it is also known to induce osteoporosis and thus increase the risk of vertebral fragility fractures. Good practice in the care of those with DMD requires prevention of these adverse effects. Treatments to increase bone mineral density include (...) bisphosphonates and vitamin D and calcium supplements, and in adolescents with pubertal delay, testosterone. Bone health management is an important part of lifelong care for patients with DMD. OBJECTIVES: To assess the effects of interventions to prevent or treat osteoporosis in children and adults with DMD taking long-term corticosteroids; to assess the effects of these interventions on the frequency of vertebral fragility fractures and long-bone fractures, and on quality of life; and to assess adverse
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women | Annals of Internal Medicine | American College of Physicians '); } Sign in below to access your subscription for full content INDIVIDUAL SIGN IN | You will be directed to acponline.org to register and create your Annals account INSTITUTIONAL SIGN (...) IN | | Subscribe to Annals of Internal Medicine . You will be directed to acponline.org to complete your purchase. Search Clinical Guidelines | 6 June 2017 Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians Free Amir Qaseem, MD, PhD, MHA; Mary Ann Forciea, MD; Robert M. McLean, MD; Thomas D. Denberg, MD, PhD; for the Clinical Guidelines Committee of the American College of Physicians ( ) Amir Qaseem
American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis ARTHRITIS & RHEUMATOLOGY Vol. 69, No. 8, August 2017, pp 1521–1537 DOI 10.1002/art.40137 V C 2017, American College of Rheumatology SPECIAL ARTICLE 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis Lenore Buckley, 1 Gordon Guyatt, 2 Howard A. Fink, 3 Michael Cannon, 4 Jennifer Grossman, 5 Karen E. Hansen, 6 Mary (...) . Results. Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendationsinthisguideline areconditional (uncertain balance between benefits and harms). Rec- ommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication(oralbisphosphonatepreferred)inadultsat moderate-to-high fracturerisk,continuing calcium plus
Treatment of Low Bone Density or Osteoporosis Treatment of Low Bone Density or Osteoporosis -- Clinical Recommendation Welcome Search Search Specify your search AAFP.org Patient Care Clinical Practice Guideline Treatment of Low Bone Density or Osteoporosis Treatment of Low Bone Density or Osteoporosis (Endorsed, April 2017) The guideline, Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women , was developed by the American College of Physicians and was endorsed (...) by the American Academy of Family Physicians. Key Recommendations Pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab should be prescribed for women with osteoporosis to reduce the risk of hip and vertebral fractures. Pharmacologic treatment should continue for five years, during which time bone density monitoring should not be done. Menopausal estrogen therapy, menopausal estrogen plus progesterone, or raloxifene should not be used in women with osteoporosis. The decision
Diagnosis and treatment of osteoporosis. Diagnosis and treatment of osteoporosis. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested (...) * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011292 2017 Jul NEATS Assessment Diagnosis and treatment of osteoporosis. Allen S, Forney-Gorman A, Homan M, Kearns A, Kramlinger A, Sauer M. Diagnosis and treatment of osteoporosis. Bloomington
An overview and management of osteoporosis 28293453 2018 11 13 2147-9720 4 1 2017 Mar European journal of rheumatology Eur J Rheumatol An overview and management of osteoporosis. 46-56 10.5152/eurjrheum.2016.048 Osteoporosis -related to various factors including menopause and aging- is the most common chronic metabolic bone disease, which is characterized by increased bone fragility. Although it is seen in all age groups, gender, and races, it is more common in Caucasians (white race), older (...) people, and women. With an aging population and longer life span, osteoporosis is increasingly becoming a global epidemic. Currently, it has been estimated that more than 200 million people are suffering from osteoporosis. According to recent statistics from the International Osteoporosis Foundation, worldwide, 1 in 3 women over the age of 50 years and 1 in 5 men will experience osteoporotic fractures in their lifetime. Every fracture is a sign of another impending one. Osteoporosis has no clinical
Cost-Effectiveness of Zoledronic Acid to Prevent and Treat Postmenopausal Osteoporosis in Comparison with Routine Medical Treatment 28163861 2018 11 13 2008-5842 8 12 2016 Dec Electronic physician Electron Physician Cost-Effectiveness of Zoledronic Acid to Prevent and Treat Postmenopausal Osteoporosis in Comparison with Routine Medical Treatment. 3434-3440 10.19082/3434 Fractures caused by osteoporosis are prevalent among elderly females, which reduce quality of life significantly. This study (...) aimed at comparing cost-effectiveness of Zoledronic acid in preventing and treating post-menopause osteoporosis as compared with routine medical treatment. This cost-effectiveness study was carried out retrospectively from the Ministry of Health and insurance organizations perspective. Costs were evaluated based on the cost estimation of a sample of patients. Outcomes were obtained from a systematic review. The Cost-Effectiveness Ratio (CER) and incremental cost-effectiveness ratio (ICER
Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness | CADTH.ca Find the information you need Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Published on: December 12, 2016 Project Number: RC0829-000 Product Line: Research (...) Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the cost-effectiveness of denosumab versus zoledronic acid in patients with osteoporosis? Key Message Two studies were identified that evaluated the cost-effectiveness of denosumab for the treatment of elderly men with osteoporosis, from a payer perspective in the United States or Sweden. Both studies found that subcutaneous denosumab 60 mg administered once every six months was associated with lower-costs
Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Denosumab versus Zoledronic Acid for Men with Osteoporosis: Clinical Effectiveness and Guidelines Published on: November 28, 2016 Project Number: RC0828-000 Product (...) Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of denosumab versus zoledronic acid in male patients with osteoporosis? What is the comparative clinical effectiveness of denosumab versus zoledronic acid in male patients with osteoporosis and non-metastatic prostate cancer receiving adjuvant anti-androgen therapy? What are the evidence-based guidelines regarding the use of denosumab and zoledronic acid
The Occurrence of Subclinical Hypercortisolism and Osteoporosis in Patients with Incidentally Discovered Unilateral and Bilateral Adrenal Tumors 28670192 2018 11 13 1452-8258 35 4 2016 Oct Journal of medical biochemistry J Med Biochem The Occurrence of Subclinical Hypercortisolism and Osteoporosis in Patients with Incidentally Discovered Unilateral and Bilateral Adrenal Tumors. 401-409 10.1515/jomb-2016-0020 Adrenal incidentalomas (AI) are clinically silent adrenal masses that are detected (...) patients (31.1% vs 15.2%, respectively, p=0.026). LS BMD was lower in BAI than in UAI patients (0.96±0.14 vs 0.87±0.15, p=0.002). There were no differences in FN BMD. The prevalence of osteoporosis was higher in BAI compared to UAI patients (37.1% vs 15.9%, respectively, p=0.011). Patients with BAI had higher prevalence of SH and osteoporosis than those with UAI. Frequency of other co-morbidities was similar. This may be due to the higher degree of autonomous cortisol secretion or different tissue
Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Description: Calcium is the dominant mineral present in bone and a shortfall nutrient in the American diet. Supplements have been recommended for persons who do not consume adequate calcium from their diet as a standard strategy for the prevention (...) of osteoporosis and related fractures. Whether calcium with or without vitamin D supplementation is beneficial or detrimental to vascular health is not known. Methods: The National Osteoporosis Foundation and American Society for Preventive Cardiology convened an expert panel to evaluate the effects of dietary and supplemental calcium on cardiovascular disease based on the existing peer-reviewed scientific literature. The panel considered the findings of the accompanying updated evidence report provided
Love your bones: finding and treating osteoporosis Love your bones: finding and treating osteoporosis - Evidently Cochrane Search and hit Go By October 20, 2016 // Today is World Osteoporosis Day. We’re taking a look at the campaign and at Cochrane evidence on osteoporosis. Be proactive and #LoveYourBones is the message of this year’s . The campaign is a call to action for members of the public to act early to protect their bone and muscle health, and for health professionals and those who fund (...) health care to prioritize osteoporosis and fracture prevention by ensuring that people who are at high risk are assessed and offered appropriate treatment. People are also being asked to raise awareness of the campaign by wearing white, not a colour that does anything for me, so instead I’m blogging some Cochrane evidence. What is osteoporosis? Osteoporosis is a condition that weakens bones through a reduction in bone mineral density (BMD), making the risk of broken bones (fractures) more likely
Romosozumab Treatment in Postmenopausal Women with Osteoporosis. BACKGROUND: Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. METHODS: We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned to receive subcutaneous injections of romosozumab (at a dose of 210 mg) or placebo monthly for 12 months; thereafter, patients in each group received denosumab (...) with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months. The lower risk of clinical fracture that was seen with romosozumab was evident at 1 year. (Funded by Amgen and UCB Pharma; FRAME ClinicalTrials.gov number, NCT01575834 .).